KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATFurniture, Fixtures and OtherGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Boston Scientific (BSX) EBIAT (2016 - 2026)

Boston Scientific's EBIAT history spans 18 years, with the latest figure at $1.3 billion for Q1 2026.

  • On a quarterly basis, EBIAT rose 99.26% to $1.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.6 billion, a 75.84% increase, with the full-year FY2025 number at $2.9 billion, up 56.66% from a year prior.
  • EBIAT hit $1.3 billion in Q1 2026 for Boston Scientific, up from $670.0 million in the prior quarter.
  • Over the last five years, EBIAT for BSX hit a ceiling of $1.3 billion in Q1 2026 and a floor of $110.0 million in Q1 2022.
  • Historically, EBIAT has averaged $492.1 million across 5 years, with a median of $493.0 million in 2024.
  • Biggest five-year swings in EBIAT: tumbled 67.74% in 2022 and later skyrocketed 260.0% in 2023.
  • Tracing BSX's EBIAT over 5 years: stood at $140.0 million in 2022, then skyrocketed by 260.0% to $504.0 million in 2023, then rose by 11.51% to $562.0 million in 2024, then increased by 19.22% to $670.0 million in 2025, then soared by 99.85% to $1.3 billion in 2026.
  • Business Quant data shows EBIAT for BSX at $1.3 billion in Q1 2026, $670.0 million in Q4 2025, and $755.0 million in Q3 2025.